Coronary Artery Disease and Renal Failure Registry

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00679419

Acronym

CAD-REF

Enrollment

3352

Registered

2008-05-16

Start date

2007-12-31

Completion date

2013-05-31

Last updated

2012-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Renal Failure

Brief summary

It is the aim of the multi-centric and prospective registry to analyze in patients with CAD the impact of different grades of renal failure on the outcome and course of the patients and to correlate these with clinical variables. In particular, the registry has the following objectives: * prospective consecutive assessment of all patients with coronary artery disease and renal failure in the participating hospitals of the registry * evaluation of the outcome and course of patients with regard to their different stages of renal failure at baseline * analysis of the impact of different therapeutic strategies on acute and long-term outcomes * identification of clinical risk factors, novel biomarkers and genetic markers for an unfavorable long-term outcome

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women and men \>= 18 years of age * Patients with actually performed interventional coronary angiography and there a documented coronary heart disease, defined as at least one documented stenosis \>= 50 % in at least one main coronary vessel (Main steam; RCX; RIVA; RCA) * European/Caucasian descent (European/Caucasian parents and grandparents) * Availability of an urine, serum- and EDTA blood sample of the patient * Documented consent of patients for handling of personal medical data, including a genetic analysis

Exclusion criteria

* Patients who have been already recruited into this registry * Patients with organ transplantations, apart from kidney transplantations * Immunosuppressive therapy, apart from immunosuppressive therapy after kidney transplantation * Patients with polycystic renal disease * Pregnant and breastfeeding patients * Known malignant tumor

Design outcomes

Primary

Measure	Time frame
all cause mortality	two years

Secondary

Measure	Time frame	Description
manner of death	two years	cardiac death; non-cardiac death; death of unknown cause

Other

Measure	Time frame	Description
Interventions	two years	Myocardial infarction or stroke; Renal failure or contrast medium induced nephropathy

Countries

Germany

Outcome results